ADVANCE
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 462 patients (estimated)
- Sponsors
- Sylvester Comprehensive Cancer Center (Main)
- Collaborators
- Amgen
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1072
- NCT Identifier
- NCT04268498
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.